**Post-Implementation Tasks:**

**What We Need to Do after a New Blood Component or Product is Introduced**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Activity** | **Date of Review** | **Performed by** | **Clinical Area/Chart Identifier** | **Compliance (Y/N\*):****\*if ‘N’, explain** |
| **Monitor the Guidelines by Chart Review** |
| All orders outside the guidelines have been reviewed |  |  |  |  |
| Other orders have correct indications |  |  |  |  |
| Correct dose |  |  |  |  |
| Complete and accurate documentation |  |  |  |  |
| Informed consent has been obtained |  |  |  |  |
| Adverse events have been charted (see next section) |  |  |  |  |
| **Monitor Adverse Events** |
| Adverse events are documented and reported |  |  |  |  |
| Adverse events are reviewed |  |  |  |  |
| Adverse events are investigated, as appropriate |  |  |  |  |
| Adverse events are presented to the TC |  |  |  |  |

V

**Post-Implementation Tasks:**

**What We Need to Do after a New Blood Component or Product is Introduced**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Activity** | **Date of Review** | **Performed by** | **List Document Reviewed** | **Compliance (Y/N\*):****\*if ‘N’, explain** |
| **Re-Evaluate SOPs, Guidelines and Policies** |
| Documents are reviewed annually |  |  |  |  |
| Documents are current and complete |  |  |  |  |
| Documents are subject to user feedback |  |  |  |  |

vi